Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold

Protein Science

Volumn 13, Issue 7, 2004, Pages 1882-1891

  Nicaise, Magali ^a   Valerio Lepiniec, Marielle ^a   Minard, Philippe ^a   Desmadril, Michel ^a  

^a INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

Camel antilysozyme; CDR3 loop; Drug targeting; Neocarzinostatin

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN; LYSOZYME; ZINOSTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG TARGETING; ENZYME BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HYDROPHOBICITY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; WILD TYPE;

ANIMALS; BACTERIAL PROTEINS; CAMELS; COMPLEMENTARITY DETERMINING REGIONS; DRUG DELIVERY SYSTEMS; MURAMIDASE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; ZINOSTATIN;

CAMELIDAE;

EID: 3042533396     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.03540504     Document Type: Article

References (46)

1. Adjadj, E., Quiniou, E., Mispelter, J., Favaudon, V., and Lhoste, J. 1992a. The seven-stranded β-barrel structure of apo-neocarzinostatin as compared to the immunoglobulin domain. Biochimie 74: 853-858.
2. -. 1992b. Three-dimensional solution structure of apo-neocarzinostatin from Streptomyces carzinostaticus determined by NMR spectroscopy. Eur. J. Biochem. 203: 505-511.
3. Bird, R., Hardman, K., Jacobson, J., Johnson, S., Kaufman, B., Lee, S., Lee, T., Pope, S., Riordan, G., and Whitlow, M. 1988. Single-chain antigen-binding proteins. Science 242: 423-426.
4. Caldas, C., Coelho, V., Kalil, J., Moro, A.M., Maranhao, A.Q., and Brigido, M.M. 2003. Humanization of the anti-CD18 antibody 6.7: An unexpected effect of a framework residue in binding to antigen. Mol. Immunol. 39: 941-952.
5. Constantine, K.L., Colson, K.L., Wittekind, M., Friedrichs, M.S., Zein, N., Tuttle, J., Langley, D.R., Leer, J.E., Schroeder, D.R., and Lam, K.S. 1994. Sequential 1H, 13C, and 15N NMR assignments and solution conformation of apokedarcidin. Biochemistry 38: 11438-11452.
6. Davies, J. and Riechmann, L. 1996. Single antibody domains as small recognition units: Design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. 9: 531-537.
7. Desmyter, A., Transue, T., Ghahroudi, M., Dao Thi, M.-H., Poortmans, F., Hamers, R., Muyldermans, S., and Wyns, L. 1996. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3: 803-811.
8. Edo, K., Saito, K., Matsuda, Y., Akiyama-Murai, Y., Mizugaki, M., Koide, Y., and Ishida, N. 1991. Neocarzinostatin: Selective tryptophan oxidation and neocarzinostatin-chromophore binding to apo-neocarzinostatin. Chem. Pharm. Bull. (Tokyo) 39: 170-176.
9. Ellis, J.H., Neil Burden, M., Vinogradov, D.V., Linge, L., and Crowe, J.S. 1996. Interactions of CD80 and CD86 with CD28 and CTLA4. J. Immunol. 158: 2700-2709.
10. Essen, L. and Skerra, A. 1994. The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model. J. Mol. Biol. 238: 226-244.
11. Ewert, S., Honegger, A., and Pluckthun, A. 2002. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry 42: 1517-1528.
12. Ewert, S., Huber, T., Honegger, A., and Pluckthun, A. 2003. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325: 531-553.
13. Gill, S.C. and von Hippel, P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182: 319-326.
14. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Bajyana Songa, E., Bendahman, N., and Hamers, R. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
15. Harris, B. 1999. Exploiting antibody-based technologies to manage environmental pollution. Trends Biotechnol. 17: 290-296.
16. Heyd, B., Lerat, G., Adjadj, E., Minard, P., and Desmadril, M. 2000. Reinvestigation of the proteolytic activity of neocarzinostatin. J. Bacteriol. 182: 1812-1818.
17. Heyd, B., Pecorari, F., Collinet, B., Adjadj, E., Desmadril, M., and Minard, P. 2003. In vitro evolution of the binding specificity of neocarzinostatin, an enediyne-binding chromoprotein. Biochemistry 42: 5674-5683.
18. Hoess, R. 1993. Phage display of peptides and protein domains. Curr. Opin. Struct. Biol. 3: 572-579.
19. Hoogenboom, H. 1997. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15: 62-70.
20. Hudson, P. 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11: 548-557.
21. Ishida, N., Miyasaki, K., Kumagai, K., and Rikimaru, M. 1965. Neocarzinostatin, an antitumor antibiotic of high molecular weight. J. Antibiot. (Tokyo) 18: 68-76.
22. Kappen, L., Napier, M., and Goldberg, I. 1980. Roles of chromophore and apo-protein in neocarzinostatin action. Proc. Natl. Acad. Sci. 77: 1970-1974.
23. Kousparou, C., Epenetos, A., and Deonarain, M. 2002. Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. Int. J. Cancer 99: 138-148.
24. Maeda, H. 2001. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46: 169-185.
25. Mohanty, S., Sieker, L., and Drobny, G. 1994. Sequential 1H NMR assignmen of the complex of aponeocarzinostatin with ethidium bromide and investigation of protein-drug interactions in the chromophore binding site. Biochemistry 33: 10579-10590.
26. Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J.A.R.G., and Hamers, R. 1994. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7: 1129-1135.
27. Nozaki, Y. 1972. The preparation of guanidine hydrochloride. Methods Enzymol. 26: 43-50.
28. Nygren, P.A. and Uhlen, M. 1997. Scaffolds for engineering novel binding sites in proteins. Curr. Opin. Struct. Biol. 7: 463-469.
29. Pace, C. 1986. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol. 131: 266-280.
30. Pace, C.N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4: 2411-2423.
31. Pletnev, V.Z. and Kuzin, A.P. 1982. Actinoxanthin structure at the atomic level. Bioorganicheskaya Khimiya 8: 1637-1643.
32. Riechman, L., Clark, M., Waldman, H., and Winter, G. 1988. Reshaping human antibodies for therapy. Nature 332: 323-327.
33. Sakata, N., Mase, T., Ikeno, S., Hori, M., and Otani, T. 1993. The amino acid sequence of actinoxanthin apoprotein deduced from the base sequence of the gene. J. Antibiot. (Tokyo) 46: 1475-1477.
34. Schauss, S., Cavalieri, D., and Myers, A. 2001. Gene transcription analysis of Saccharomyces cerevisiae exposed to neocarzinostatin protein-chromophore complex reveals evidence of DNA damage, a potential mechanism of resistance, and consequences of prolonged exposure. Proc. Natl. Acad. Sci. 98: 11075-11080.
35. Schiweck, W. and Skerra, A. 1995. Fermenter production of an artificial fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins 23: 561-565.
36. Skerra, A. 2000. Engineered protein scaffolds for molecular recognition. J. Mol. Recognit. 13: 167-187.
37. Smith, G.P. 1991. Surface presentation of protein epitopes using bacteriophage expression systems. Curr. Opin. Biotechnol. 2: 668-673.
38. Spinelli, S., Frenken, L., Bourgeois, D., de Ron, L., Bos, W., Verrips, T., Anguille, C., Cambillau, C., and Tegoni, M. 1996. The crystal structure of a llama heavy chain variable domain. Nat. Struct. Biol. 3: 752-757.
39. Sudhahar, G.C., Balamurugan, K., and Chin, D.H. 2000. Release of the neocarzinostatin chromophore from the holoprotein does not require major conformational change of the tertiary and secondary structures induced by trifluoroethanol. J. Biol. Chem. 275: 39900-39906.
40. Transue, T., De Genst, E., Ghahroudi, M., Wyns, L., and Muyldermans, S. 1998. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins 32: 515-522.
41. Urbaniak, M., Muskett, F., Finucane, M., Caddick, S., and Woolfson, D. 2002. Solution structure of a novel chromoprotein derived from apo-neocarzinostatin and a synthetic chromophore. Biochemistry 41: 11731-11739.
42. Valerio-Lepiniec, M., Nicaise, M., Adjadj, E., Minard, P., and Desmadril, M. 2002. Key interactions in neocarzinostatin, a protein of the immunoglobulin fold family. Protein Eng. 15: 861-869.
43. van den Beucken, T., van Neer, N., Sablon, E., Desmet, J., Celis, L., Hoogenboom, H.R., and Hufton, E. 2001. Building novel binding ligands to B7,1 and B7,2 based on human antibody single variable light chain domains. J. Mol. Biol. 310: 591-601.
44. Van Roey, P. and Beerman, T.A. 1989. Crystal structure analysis of auromomycin apoprotein (macromomycin) shows importance of protein side chains to chromophore binding selectivity. Proc. Natl. Acad. Sci. 86: 6587-6591.
45. Wells, J. and Lowman, H. 1992. Rapid evolution of peptide and protein binding properties in vitro. Curr. Opin. Biotechnol. 3: 355-362.
46. Xu, J., Baase, W.A., Baldwin, E., and Matthews, B.W. 1994. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 33: 5947-5954.